Biomarker‐Guided Individualization of Antibiotic Therapy
Open Access
- 9 February 2021
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (2) , 346-360
Abstract
Treatment failure of antibiotic therapy due to insufficient efficacy or occurrence of toxicity is a major clinical challenge, and is expected to become even more urgent with the global rise of antibiotic resistance. Strategies to optimize treatment in individual patients are therefore of crucial importance. Currently, therapeutic drug monitoring plays an important role in optimizing antibiotic exposure to reduce treatment failure and toxicity. Biomarker‐based strategies may be a powerful tool to further quantify and monitor antibiotic treatment response, and reduce variation in treatment response between patients. Host response biomarkers, such as CRP, procalcitonin, IL‐6, and presepsin, could potentially carry significant information to be utilized for treatment individualization. To achieve this, the complex interactions among immune system, pathogen, drug, and biomarker need to be better understood and characterized. The purpose of this tutorial is to discuss the use and evidence of currently available biomarker‐based approaches to inform antibiotic treatment. To this end, we also included a discussion on how treatment response biomarker data from preclinical, healthy volunteer, and patient‐based studies can be further characterized using pharmacometric and system pharmacology based modeling approaches. As an illustrative example of how such modeling strategies can be used, we describe a case study in which we quantitatively characterize procalcitonin dynamics in relation to antibiotic treatments in patients with sepsis.Keywords
This publication has 98 references indexed in Scilit:
- Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients - calculated sample size: 1816 patientsBMC Infectious Diseases, 2013
- Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections2012
- C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational studyCritical Care, 2011
- Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System InfectionsClinical Microbiology Reviews, 2010
- Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studiesNature Biotechnology, 2010
- Next-generation biomarkers for detecting kidney toxicityNature Biotechnology, 2010
- Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trialThe Lancet, 2010
- Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised studyEuropean Respiratory Journal, 2009
- Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trialCritical Care, 2009
- The influence of corticosteroids on the release of novel biomarkers in human endotoxemiaIntensive Care Medicine, 2007